Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: https://www.modular-medical.com
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4/A - Modular Medical, Inc. (0001074871) (Issuer)
4/A - Modular Medical, Inc. (0001074871) (Issuer)
4/A - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U. S. Food and Drug Administration ("FDA") clearance of its MODD1 pump, as well as next steps and milestones.Conference Call and Webcast InformationDate: September 5, 2024Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Conference Call Number: 1-88
MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetesDesigned to be simpler and more affordable to expand access to diabetes technology for previously underserved communitiesCommercial availability expected in early 2025 SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States. With its comme
SAN DIEGO, CA / ACCESSWIRE / January 19, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the premarket submission of its MODD1 next-generation insulin pump to the FDA for 510(k) clearance."This is an exciting milestone for the Company, as we seek to change the diabetes market. Almost 30 years after the introduction of the first insulin pump, more than three quarters of those who could benefit from wearing a pump do not wear one. It is our belief that our simplified design will encourage many "a
8-K - Modular Medical, Inc. (0001074871) (Filer)
8-K - Modular Medical, Inc. (0001074871) (Filer)
10-Q - Modular Medical, Inc. (0001074871) (Filer)
424B5 - Modular Medical, Inc. (0001074871) (Filer)
10-K - Modular Medical, Inc. (0001074871) (Filer)
S-8 - Modular Medical, Inc. (0001074871) (Filer)
8-K - Modular Medical, Inc. (0001074871) (Filer)
424B5 - Modular Medical, Inc. (0001074871) (Filer)
8-K - Modular Medical, Inc. (0001074871) (Filer)
424B5 - Modular Medical, Inc. (0001074871) (Filer)
SC 13G - Modular Medical, Inc. (0001074871) (Subject)
SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13G/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13G/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13G - Modular Medical, Inc. (0001074871) (Subject)
SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalizatio
SAN DIEGO, CA / ACCESSWIRE / July 6, 2023 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced the appointment of medical device industry leader Duane DeSisto to its board of directors. Mr. DeSisto was previously President, CEO and Director of Insulet Corporation, developers of the groundbreaking OmniPod Insulin Management System, before retiring in 2014."Duane brings more than 25 years of experience in the medical device industry and is a visionary business leader credited with the launch and transformatio
Schmid brings 40 years of experience in medical devices for drug delivery and diabetes management and a background in high-volume manufacturingSAN DIEGO, CA / ACCESSWIRE / July 26, 2022 / Modular Medical, Inc. (the "Company" or "Modular Medical")(NASDAQ:MODD) today announced that it has appointed industry veteran Kevin Schmid as its Chief Operating Officer. Mr. Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the Omnipod Diabete
Lynn Vos to remain on board of directors Besser brings 25 years of experience in life sciences, technology, capital markets Company reaffirms timeline for 510(k) submission of MODD1 insulin pump to FDASAN DIEGO, CA / ACCESSWIRE / February 24, 2022 / Modular Medical, Inc. (the "Company" or "Modular Medical")(NASDAQ:MODD) today announced that its board of directors has appointed James "Jeb" Besser as Chief Executive Officer. Besser, a company development and capital markets veteran, has served 23 years as managing member of Manchester Management LLC, the Company's largest outside shareholder and development partner since its inception. Lynn Vos, the Company's CEO since August of 2021, will rem
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024-Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations-CEO to discuss further details of the program in Tribe Public Webinar on Wednesday, September 11 at 8:30 a.m. Pacific time SAN DIEGO, CA / ACCESSWIRE / September 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user friendly and affordable design, today announced
SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U. S. Food and Drug Administration ("FDA") clearance of its MODD1 pump, as well as next steps and milestones.Conference Call and Webcast InformationDate: September 5, 2024Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Conference Call Number: 1-88
MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetesDesigned to be simpler and more affordable to expand access to diabetes technology for previously underserved communitiesCommercial availability expected in early 2025 SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States. With its comme
The global diabetes care market, valued at $18.9 billion in 2023, is projected to reach $35.8 billion by 2028The insulin pump segment is expected to grow from $5.26 billion to $21.65 billion by 2032Discover how Modular Medical is accelerating the development of technology to empower the whole diabetes community with MODD1Meet with Modular Medical CEO Jeb BesserSAN DIEGO, CA / ACCESSWIRE / August 8, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that Jeb Besser, CEO of Modular Medical, will pre
SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch the next generation of easy-to-use, prescribe and live with affordable insulin pump technology, today announced it has begun the transfer of its pilot line manufacturing operations to a Phillips Medisize manufacturing site in Queretaro, Mexico.Phillips Medisize, a Molex company, has been an outstanding collaborator in the development of Modular Medical's platform product, supply chain and manufacturing operations, as the Company intends to transition from pre-commercial production to high-volume device manufa
Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations SAN DIEGO, CA / ACCESSWIRE / July 15, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced a proof-of-concept study with Gubra A/S ("Gubra") in a high-fat, diet-induced obese ("DIO") mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent ef
SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalizatio
SAN DIEGO, CA / ACCESSWIRE / May 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.Company WebcastThe Company's webcasted presentation will take place at 3:30 p.m. ET on Thursday, May 30, 2024. The webcast can be accessed by visiting the conference home page at http://lythampartners.com/spring2024/ and will also be av
SAN DIEGO, CA / ACCESSWIRE / March 26, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the addition of Steve Gemmell as Vice President of Engineering.Gemmell has over 20 years of experience in medical device product development and operations and previously held R&D leadership positions with Cytrellis Biosystems, Inc., Onduo, a joint venture between Sanofi SA and Verily Life Sciences, and Insulet Corporation. He has significant expertise in automated insulin delivery, and, in his past positions
Meet with Modular Medical CEO, Jeb BesserThere are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US. 100% of patient population require daily insulin injection. Only 20% currently use an insulin pump.Discover how Modular Medical is developing technology to empower the community of people with diabetes by offering a simple yet effective Insulin delivery device, MODD1SAN DIEGO, CA / ACCESSWIRE / March 4, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announ
Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. Harrow (NASDAQ:HROW) shares rose 13.5% to $13.7. The market value of their outstanding shares is at $484.7 million. As per the press release, Q1 earnings came out today. Vaxart (NASDAQ:VXRT) stock moved upwards by 12.19% to $0.92. The market value of their outstanding shares is at $162.6 million. The company's, Q1 earnings came out today. Modular Medical (NASDAQ:MODD) shares moved upwards by 7.77% to $1.94. The market value of their outstanding shares is at $60.1 million. Gossamer Bio (NASDAQ:GOSS) stoc
Gainers Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The market value of their outstanding shares is at $12.0 million. Fresh2 Group (NASDAQ:FRES) stock moved upwards by 5.26% to $0.6. The company's market cap stands at $14.2 million. Biora Therapeutics (NASDAQ:BIOR) shares rose 5.12% to $1.23. The company's market cap stands at $33.4 million. As per the news, the Q4 earnings report came out yesterday. Athira Pharma (NASDAQ:ATHA) stock rose 5.07% to $2.69. The market value of their outstanding shares is at $103.0 million. Clearside Biomedical (NASDAQ:CLSD) stock rose 4.79% to $1.75. The company's market cap stands at $1
Benchmark analyst Bruce Jackson reiterates Modular Medical (NASDAQ:MODD) with a Speculative Buy and maintains $5 price target.
Gainers Applied Therapeutics (NASDAQ:APLT) stock rose 42.5% to $5.34 during Monday's regular session. The market value of their outstanding shares is at $412.7 million. Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 41.86% to $2.44. The market value of their outstanding shares is at $8.8 million. Modular Medical (NASDAQ:MODD) shares moved upwards by 38.24% to $1.74. The market value of their outstanding shares is at $37.9 million. The company's, Q3 earnings came out 4 days ago. Equillium (NASDAQ:EQ) shares increased by 37.72% to $2.78. The market value of their outstanding shares is at $97.7 million. Phathom Pharmaceuticals (NASDAQ:PHAT) shares moved upwards by 34.34% to $9.27
Gainers OneMedNet (NASDAQ:ONMD) shares rose 91.2% to $1.44 during Friday's regular session. The market value of their outstanding shares is at $46.4 million. Applied Therapeutics (NASDAQ:APLT) stock increased by 28.53% to $4.82. The market value of their outstanding shares is at $372.2 million. Modular Medical (NASDAQ:MODD) stock moved upwards by 24.58% to $1.56. The company's market cap stands at $34.2 million. As per the press release, Q3 earnings came out 3 days ago. Prelude Therapeutics (NASDAQ:PRLD) shares moved upwards by 23.27% to $4.29. The company's market cap stands at $235.2 million. Ocugen (NASDAQ:OCGN) shares rose 21.98% to $0.91. The company's market cap stands at $233.4 m
Modular Medical has priced its underwritten public offering (the "offering") of 9,090,910 shares of its common stock, led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical's Chief Executive Officer, and Morgan Frank, a member of the Company's board of directors, and other existing institutional investors. The shares of common stock are being sold at a price to the public of $1.10 per share. In addition, Modular Medical has granted the underwriter a 30-day option to purchase up to 1,321,989 additional shares of its common stock.
Gainers China Pharma Holding (AMEX:CPHI) shares rose 12.7% to $0.12 during Thursday's after-market session. The market value of their outstanding shares is at $6.5 million. SenesTech (NASDAQ:SNES) shares moved upwards by 7.54% to $1.14. Lucy Scientific Discovery (NASDAQ:LSDI) stock increased by 6.43% to $0.21. The company's market cap stands at $3.7 million. As per the press release, Q2 earnings came out yesterday. OneMedNet (NASDAQ:ONMD) shares rose 6.24% to $0.8. The company's market cap stands at $25.8 million. Universe Pharmaceuticals (NASDAQ:UPC) shares rose 5.26% to $1.8. The company's market cap stands at $6.5 million. Vaxxinity (NASDAQ:VAXX) shares moved upwards by 4.99% to $0.
Gainers KalVista Pharma (NASDAQ:KALV) stock moved upwards by 31.5% to $21.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $729.1 million. Jin Medical International (NASDAQ:ZJYL) stock moved upwards by 25.75% to $10.45. The company's market cap stands at $1.6 billion. Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 21.37% to $1.76. The market value of their outstanding shares is at $4.6 million. Iterum Therapeutics (NASDAQ:ITRM) stock increased by 21.01% to $1.9. The market value of their outstanding shares is at $25.5 million. Modular Medical (NASDAQ:MODD) shares rose 17.85% to $1.65. The market value of their outstanding shares is at $35.0 mil